Abstract
Breast cancer is a group of diseases in which cells divide out of controlled, typically resulting in a mass. Erlotinib is targeted cancer drug which functions as an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is used mainly to treat of non-small cell lung cancer patients and has an action against pancreatic cancer. Vorinostat (aka suberanilohydroxamic acid) is an inhibitor of histone deacetylases (HDAC), which has an epigenetic modulation activity. It is used to treat cutaneous T cell lymphoma. In the present study, the erlotinib (ERL) and vorinostat (SAHA) loaded TiO2 nanoparticles (NPs) were used for the treatment of the breast cancer cells (MDA-MB-231 and MCF-7) and human cancerous amniotic cells (WISH). Cell count and viability were negatively affected in all treatments compared to normal cells and bare TiO2 NPs. Apoptosis results indicated a significant increase in the total apoptosis in all treatments compared with control cells. ERL- and SAHA-loaded TiO2 NPs treatments arrested breast cancer cells at G2/M phase, which indicate the cytotoxic effect of these treatment. Partner and localizer of BRCA2 (PALB2) gene expression was assessed using qPCR. The results indicate that PLAB2 was upregulated in ERL- and SAHA-loaded TiO2 NPs compared with control cells and can be used as nanocarrier for chemotherapy drugs. However, this conclusion necessitates further confirmative investigation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdel-Ghany S, Mahfouz M, Ashraf N, Sabit H, Cevik E, El-Zawahri M (2020) Gold nanoparticles induce G2/M cell cycle arrest and enhance the expression of E-cadherin in breast cancer cells. Inorg Nano-Metal Chem. https://doi.org/10.1080/24701556.2020.1728553
Abdel-Hakeem MA, Abdel-Haseb OM, Abdel-Ghany SE, Cevik E, Sabit H (2020) Doxorubicin loaded on chitosan-protamine nanoparticles triggers apoptosis via downregulating Bcl-2 in breast cancer cells. J Drug Deliv Sci Technol 55:101423. https://doi.org/10.1016/j.jddst.2019.101423
Ali AAA et al (2016) Erlotinib-conjugated iron oxide nanoparticles as a smart cancer-targeted theranostic probe for MRI. Sci Rep 6:36650. https://doi.org/10.1038/srep36650
Banerjee NS, Moore DW, Broker TR, Chow LT (2018) Vorinostat, a pan-HDAC inhibitor, abrogates productive HPV-18 DNA amplification. Proc Natl Acad Sci USA 115:E11138–e11147. https://doi.org/10.1073/pnas.1801156115
Bellarosa D, Bressan A, Bigioni M, Parlani M, Maggi CA, Binaschi M (2012) SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line. Int J Oncol 41:1486–1494. https://doi.org/10.3892/ijo.2012.1551
Biola-Clier M, Gaillard J-C, Rabilloud T, Armengaud J, Carriere M (2020) Titanium dioxide nanoparticles alter the cellular phosphoproteome in A549 cells. Nanomaterials (Basel) 10:185. https://doi.org/10.3390/nano10020185
Bogdan J, Pławińska-Czarnak J, Zarzyńska J (2017) Nanoparticles of titanium and zinc oxides as novel agents in tumor treatment: a review. Nanoscale Res Lett 12:1–15. https://doi.org/10.1186/s11671-017-2007-y
Bowman-Colin C et al (2013) Palb2 synergizes with Trp53 to suppress mammary tumor formation in a model of inherited breast cancer. Proc Natl Acad Sci USA 110:8632–8637. https://doi.org/10.1073/pnas.1305362110
Cardoso BA, Ramos TL, Belo H, Vilas-Boas F, Real C, Almeida AM (2019) Vorinostat synergizes with antioxidant therapy to target myeloproliferative neoplasms. Exp Hematol 72:60–71.e11. https://doi.org/10.1016/j.exphem.2019.02.002
Cheung BB et al (2015) Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. Mol Oncol 9:1484–1500. https://doi.org/10.1016/j.molonc.2015.04.005
El-Said KS, Ali EM, Kanehira K, Taniguchi A (2014) Molecular mechanism of DNA damage induced by titanium dioxide nanoparticles in toll-like receptor 3 or 4 expressing human hepatocarcinoma cell lines. J Nanobiotechnol 12:48–48. https://doi.org/10.1186/s12951-014-0048-2
Gangopadhyay M, Mukhopadhyay SK, Karthik S, Barman S, Pradeep Singh ND (2015) Targeted photoresponsive TiO2-coumarin nanoconjugate for efficient combination therapy in MDA-MB-231 breast cancer cells: Synergic effect of photodynamic therapy (PDT) and anticancer drug chlorambucil. MedChemComm 6:769–777. https://doi.org/10.1039/c4md00481g
Hu CMJ, Aryal S, Zhang L (2010) Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic Delivery 1:323–334. https://doi.org/10.4155/tde.10.13
Hu G et al (2016) Utilizing G2/M retention effect to enhance tumor accumulation of active targeting nanoparticles. Sci Rep 6:27669–27669. https://doi.org/10.1038/srep27669
Jeannot V et al (2016) Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. Onco Targets Ther 9:6843–6855. https://doi.org/10.2147/ott.S117743
Kang T-S, Smith AP, Taylor BE, Durstock MF (2009) Fabrication of highly-ordered TiO2 nanotube arrays and their use in dye-sensitized solar cells. Nano Lett 9:601–606. https://doi.org/10.1021/nl802818d
Karachaliou N et al (2019) Association of PALB2 messenger RNA expression with platinum-docetaxel efficacy in advanced non–small cell lung cancer. J Thorac Oncol 14:304–310. https://doi.org/10.1016/j.jtho.2018.10.168
Lagopati N, Tsilibary E-P, Falaras P, Papazafiri P, Pavlatou EA, Kotsopoulou E, Kitsiou P (2014) Effect of nanostructured TiO2 crystal phase on photoinduced apoptosis of breast cancer epithelial cells. Int J Nanomed 9:3219–3230. https://doi.org/10.2147/ijn.s62972
Lee T-G, Jeong E-H, Kim SY, Kim H-R, Kim CH (2015) The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer. Int J Cancer 136:2717–2729. https://doi.org/10.1002/ijc.29320
Lee JYC et al (2016) Inhibition of HDAC3-and HDAC6-promoted survivin expression plays an important role in saha-induced autophagy and viability reduction in breast cancer cells. Front Pharmacol 7:13. https://doi.org/10.3389/fphar.2016.00081
Lewis KA, Jordan HR, Tollefsbol TO (2019) Effects of SAHA and EGCG on growth potentiation of triple-negative breast cancer cells cancers 11:22. https://doi.org/10.3390/cancers11010023
Li J, Li M, Chen P, Ba Q (2018a) High expression of PALB2 predicts poor prognosis in patients with advanced breast cancer. FEBS Open Bio 8:56–63. https://doi.org/10.1002/2211-5463.12356
Li Z, Qiu Y, Lu W, Jiang Y, Wang J (2018b) Immunotherapeutic interventions of triple negative breast cancer. J Transl Med. https://doi.org/10.1186/s12967-018-1514-7
Lotfian H, Nemati F (2016) Cytotoxic effect of TiO2 nanoparticles on breast cancer cell line (MCF-7). IIOAB J 7:219–224
Momenimovahed Z, Salehiniya H (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press) 11:151–164. https://doi.org/10.2147/BCTT.S176070
Munster PN et al (2011) A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer 104:1828–1835. https://doi.org/10.1038/bjc.2011.156
Natarajan V, Wilson CL, Hayward SL, Kidambi S (2015) Titanium dioxide nanoparticles trigger loss of function and perturbation of mitochondrial dynamics in primary hepatocytes. PLoS ONE 10:e0134541–e0134541. https://doi.org/10.1371/journal.pone.0134541
Natarajan U, Venkatesan T, Radhakrishnan V, Samuel S, Rathinavelu A (2019) Differential mechanisms of cell death induced by HDAC inhibitor SAHA and MDM2 inhibitor RG7388 in MCF-7 cells. Cells 8:22. https://doi.org/10.3390/cells8010008
Nepomuceno TC, De Gregoriis G, de Oliveira FMB, Suarez-Kurtz G, Monteiro AN, Carvalho MA (2017) The role of PALB2 in the DNA damage response and cancer predisposition. Int J Mol Sci. https://doi.org/10.3390/ijms18091886
Ortega E et al (2020a) An erlotinib gold(I) conjugate for combating triple-negative breast cancer. J Inorg Biochem 203:10. https://doi.org/10.1016/j.jinorgbio.2019.110910
Ortega E et al (2020b) An Erlotinib gold(I) conjugate for combating triple-negative breast cancer. J Inorg Biochem 203:110910. https://doi.org/10.1016/j.jinorgbio.2019.110910
Osborne C et al (2018) Ixabepilone and carboplatin for hormone receptor positive/HER2-neu negative and triple negative metastatic breast cancer. Clin Breast Cancer 18:e89–e95. https://doi.org/10.1016/j.clbc.2017.07.002
Park S, Cho BB, Anusha JR, Jung S, Raj CJ, Kim BC, Yu KH (2020) Synthesis of Cu-64-radiolabeled folate-conjugated iron oxide nanoparticles for cancer diagnosis. J Nanosci Nanotechnol 20:2040–2044. https://doi.org/10.1166/jnn.2020.17205
Poumpouridou N et al (2016) Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer. Clin Biochem 49:253–259. https://doi.org/10.1016/j.clinbiochem.2015.10.009
Qin J et al (2019) Erlotinib Resistance with EGFR L858R/Y891D double mutation in a patient with non–small cell lung cancer. J Thorac Oncol 14:e65–e68. https://doi.org/10.1016/j.jtho.2018.12.031
Reguart N et al (2014) Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer 84:161–167. https://doi.org/10.1016/j.lungcan.2014.02.011
Ruttala HB et al (2017) Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy. Oncotarget 8:14925–14940. https://doi.org/10.18632/oncotarget.14742
Setyawati MI, Sevencan C, Bay BH, Xie JP, Zhang YB, Demokritou P, Leong DT (2018) Nano-TiO2 drives epithelial-mesenchymal transition in intestinal epithelial cancer cells. Small 14:13. https://doi.org/10.1002/smll.201800922
Shi J, Votruba AR, Farokhzad OC, Langer R (2010) Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett 10:3223–3230. https://doi.org/10.1021/nl102184c
Su JK, Byeong MK, Young JL, Hai WC (2008) Titanium dioxide nanoparticles trigger p53-mediated damage response in peripheral blood lymphocytes. Environ Mol Mutagen 49:399–405. https://doi.org/10.1002/em.20399
Tran AT et al (2019) MiR-35 buffers apoptosis thresholds in the C. elegans germline by antagonizing both MAPK and core apoptosis pathways. Cell Death Different 26:2637–2651. https://doi.org/10.1038/s41418-019-0325-6
Wu S, Luo Z, Yu PJ, Xie H, He YW (2016) Suberoylanilide hydroxamic acid (SAHA) promotes the epithelial mesenchymal transition of triple negative breast cancer cells via HDAC8/FOXA1 signals. Biol Chem 397:75–83. https://doi.org/10.1515/hsz-2015-0215
Wu P-F, Gao W-W, Sun C-L, Ma T, Hao J-Q (2020) Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer. Chin Med J 133:1304–1311. https://doi.org/10.1097/cm9.0000000000000823
Young CS, Clarke KM, Kettyle LM, Thompson A, Mills KI (2017) Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy Oncotarget 8:51429–51446. https://doi.org/10.18632/oncotarget.18009
Yu HC et al (2014) Erlotinib derivative inhibits hepatocellular carcinoma by targeting CIP2A to reactivate protein phosphatase 2A. Cell Death Dis 5:e1359. https://doi.org/10.1038/cddis.2014.325
Zhang J, Zong Y, Xu GZ, Xing K (2016) Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J 37:1184–1190. https://doi.org/10.15537/smj.2016.11.16267
Zhou J, Rossi J (2017) Aptamers as targeted therapeutics: current potential and challenges Nature reviews Drug discovery 16:181–202. https://doi.org/10.1038/nrd.2016.199
Zhou Z, Kennell C, Jafari M, Lee J-Y, Ruiz-Torres SJ, Waltz SE, Lee J-H (2017) Sequential delivery of erlotinib and doxorubicin for enhanced triple negative Breast cancer treatment using polymeric nanoparticle. Int J Pharm 530:300–307. https://doi.org/10.1016/j.ijpharm.2017.07.085
Zhou X et al (2019) SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy. J Drug Target 27:306–314. https://doi.org/10.1080/1061186x.2018.1519028
Zugazagoitia J et al (2013) Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice. Oncology (Switzerland) 84:255–264. https://doi.org/10.1159/000346534
Author information
Authors and Affiliations
Contributions
SA, EFM, and SR: conducted the experimental work, EC, OAS, and AB: interpreted the analyzed and tabulated the obtained data, HS: conceptualized the idea and wrote the manuscript, HT, AS, and HS: revised the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Abdel-Ghany, S., Raslan, S., Tombuloglu, H. et al. Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via PALB2 upregulation. 3 Biotech 10, 407 (2020). https://doi.org/10.1007/s13205-020-02391-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13205-020-02391-2